Various approaches to leveraging the human body’s own immune system to overcome tumor evasion are revolutionizing how cancer is treated. Cell and gene based immunotherapy treatments have the potential to generate long-term survival as significant response rates and durable remissions are occurring in both monotherapy and combination therapies for several different tumor types. Despite the successes in clinical trials, there are numerous challenges associated with the development, quality control, manufacturing and cost-effective use of cellular and genetic immunotherapies.
Please join us and share your expert insights into the exciting, rapidly evolving field of cellular and genetic based immunotherapies.
What is the current biggest challenge (s),outside of logistics for cellular/genetic immunotherapies?
Will edited T-cells ever show commercial promise for solid tumours?
Will CAR or TCR modified cells be the most effective immunotherapy treatment?
Will non-viral methods replace viral methods for editing cells?
What role do advanced cell and tissue models (eg 3D cultures) play in driving translational research for cellular/genetic immunotherapies?
Will costs ever be reduced to where cellular and gene based immunotherapies could have wider usage?
With the US and the EU approving the first CAR T-cell immunotherapies, how do you see the global landscape shaping up over the next 5 or 10 years? Which country/region will be leading discovery efforts in cell and gene based immunotherapies?
Senior Vice President
Product and Portfolio Strategy Astellas